Diplomats love a good existential threat. It justifies the champagne, the photo-ops, and the sweeping, non-binding communiqués that characterize high-level summits. For years, global health bureaucrats have claimed that the G7 presidency offers a historic window of opportunity for nations like France to elevate antimicrobial resistance (AMR) into a strategic health security priority.
They are wrong. Dead wrong. For a different view, check out: this related article.
Treating antibiotic resistance as a diplomatic flagship project at the G7 is a catastrophic waste of political capital. The belief that a club of wealthy nations can top-down their way out of a biological evolution crisis is a dangerous fantasy. It misdiagnoses the problem, misallocates resources, and ignores the brutal economic realities of drug development.
I have spent years analyzing global health supply chains and watching international forums burn through millions of dollars on "awareness roadmaps" while the actual pipeline for new antibiotics remains completely dry. If we keep relying on the G7 to save us from superbugs, we are going to slide right back into the medical dark ages. Related reporting on this trend has been provided by CDC.
The Flawed Premise of Diplomatic Exceptionalism
The standard argument goes like this: if we can just get the heads of state from the world’s richest economies to sign a joint declaration, we can coordinate global surveillance, fund new research, and restrict the overuse of existing antibiotics.
This ignores how bacteria actually evolve and how global markets operate.
AMR is not a treaty problem. It is a market failure combined with relentless natural selection. The G7 represents less than 10% of the world’s population. Meanwhile, the epicenter of antibiotic consumption and subsequent resistance generation has shifted drastically to middle-income and developing economies.
Imagine a scenario where the G7 perfectly regulates antibiotic use within its borders. It changes nothing. The massive, unregulated over-the-counter sales of colistin and third-generation cephalosporins in structural hotspots across South Asia and Latin America will continue to breed resistant strains that can cross the globe on a single commercial flight.
By framing AMR as a luxury security issue for wealthy nations to manage via committees, we guarantee ineffective policies.
The Push-Pull Subsidy Myth
For a decade, the consensus among G7 advisory boards has focused on "push" and "pull" incentives. Push incentives fund early-stage research. Pull incentives, like the proposed "subscription models" where governments pay a fixed fee for access to new antibiotics regardless of volume used, are supposed to guarantee a market for pharmaceutical companies.
Let’s look at the actual data instead of the economic models.
In 2019, a company called Achaogen won FDA approval for Zemdri, a breakthrough antibiotic targeting multi-drug resistant infections. It took fifteen years and hundreds of millions of dollars to develop. Because global health bodies rightly demanded that the drug be kept on the shelf as a absolute last resort to prevent resistance, the company made less than a million dollars in sales in its first quarter. Achaogen went bankrupt months later.
The market told the world exactly what it thought of new antibiotics: they are financially toxic.
The G7’s solution? More pilot programs and small-scale subscription trials. The UK tried a small-scale "Netflix model" for antibiotics, which was a step in the right direction but lacked the scale to alter global investment portfolios. Big Pharma has almost entirely abandoned the space. In the 1980s, there were over 18 major pharmaceutical companies developing antibiotics. Today, there are a handful, mostly highly fragile biotech startups running out of cash.
A G7 declaration cannot fix a broken capital model. No board of directors at a major pharmaceutical multinational is going to pivot their R&D budget from lucrative, lifelong oncology or autoimmune therapies back to a one-week course of antibiotics just because a group of prime ministers held a press conference in Biarritz or Hiroshima.
The Wrong Questions About "Rational Use"
If you look at the questions regulators and public health advocates constantly ask, the bias is obvious:
- "How do we stop doctors from over-prescribing antibiotics?"
- "How do we restrict agricultural use in livestock?"
These questions sound reasonable, but they attack the wrong end of the problem.
Dismantling the Over-Prescription Scapegoat
Yes, unnecessary prescriptions for viral respiratory infections are a problem. But focusing the bulk of our policy energy here is a form of regulatory laziness. It is easy to scold local GPs. It is much harder to fix the structural incentives of global agriculture or the lack of rapid diagnostic infrastructure.
In most of the developing world, antibiotics are used as a cheap substitute for hygiene. When a farm cannot afford modern biosecurity measures to keep thousands of chickens from getting sick in crowded conditions, they dump low-dose tetracycline into the water supply. This is not "misuse" in the eyes of the farmer; it is an economic survival mechanism.
Furthermore, without rapid, point-of-care diagnostics that can differentiate between a bacterial and viral infection in ten minutes for under five dollars, doctors in underfunded clinics will always prescribe broad-spectrum antibiotics. They cannot risk a patient dying of sepsis while waiting three days for a lab culture.
The G7 focuses on high-level governance frameworks when it should be obsessed with manufacturing cheap, bulletproof diagnostic hardware.
The Hidden Cost of the Bureaucratic Pipeline
We must acknowledge the downside of walking away from the international summit model. If we stop using the G7 to drive the AMR agenda, we lose the centralized, high-level political attention that can occasionally unlock large tranches of emergency funding. Without that spotlight, AMR risks falling behind climate change or immediate pandemic preparedness in the hierarchy of global concerns.
But that spotlight is currently an illusion. It creates a false sense of progress.
We are trading actual, concrete execution for the appearance of action. Millions of dollars that could directly fund clinical trials or subsidize factory upgrades to stop antibiotic manufacturing plants in India from dumping active pharmaceutical ingredients into local waterways are instead spent on hosting delegate dinners, drafting white papers, and funding "coordination secretariats."
The bureaucracy has become self-serving. It measures success by the number of nations that adopt a "National Action Plan," not by the number of new chemical entities entering Phase I clinical trials.
A Brutal, Actionable Alternative
If we want to stop a future where a scratched finger can lead to a fatal infection, we must bypass the diplomatic theater entirely and execute a hard pivot toward raw industrial policy.
1. Nationalize the Antibiotic Pipeline
If the private market cannot make money selling antibiotics, stop trying to bribe them with small pull incentives. Governments need to treat antibiotic development the same way they treat advanced defense procurement or nuclear submarine construction. We do not expect private defense contractors to build fighter jets and then make a profit by selling them on the open market; the state pays for the development, owns the IP, and maintains the strategic reserve.
A coalition of willing nations should directly fund state-owned or heavily subsidized, non-profit drug development houses explicitly designed to discover, manufacture, and stockpile new classes of antibiotics.
2. Radical Decoupling of Diagnostics and Drugs
We must ban the sale of any new, critically important antibiotic unless it is bundled with a mandatory, low-cost companion diagnostic test. If a healthcare system cannot prove the infection is susceptible to that specific drug via an objective test, the drug remains locked. This completely changes the economic equation from "volume of pills sold" to "precision of delivery."
3. Supply Chain Hardening via Procurement Leverage
Instead of begging foreign factories to stop polluting the environment with antibiotic residue—which accelerates resistance in the wild—large state buyers like the US Medicare system or European national health services must use their massive procurement power. They must immediately disqualify any pharmaceutical supplier that cannot prove its entire supply chain adheres to zero-liquid-discharge standards. Money talks louder than any G7 communiqué.
Stop expecting a rotating presidency of a political talking shop to solve a fundamental crisis of biology and economics. The G7 cannot negotiate with natural selection. It is time to stop drafting resolutions and start building factories. Do not look to the diplomats; they are looking to the next summit. This requires raw industrial execution, cold hard cash, and the political courage to accept that the old market models are dead.
